Kiniksa Pharmaceuticals International Plc (KNSA) Return on Investment ROI from the third quarter of 2026 to third quarter of 2025 and for the year 2026, average high and low, overall ranking from Sep 30 2026 to Sep 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Kiniksa Pharmaceuticals International Plc  (NASDAQ: KNSA)


Kiniksa Pharmaceuticals International Plc's ROI from its third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Kiniksa Pharmaceuticals International Plc's ROI in the third quarter of 2026?
Kiniksa Pharmaceuticals International Plc achieved a return on average invested assets (ROI) of 15.6 % in its third quarter of 2026, this is above KNSA's average return on investment of -11.61%.
Kiniksa Pharmaceuticals International Plc invested over the 12 months ending in its third quarter of 2026 $702 million

ROI has improved compared to 12.38% in the second quarter of 2026, due to net income growth.

Within the Healthcare sector 33 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Sep 30 2026 quarter, so far to 269, from total ROI ranking in the second quarter of 2026 at 582.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Sep 30 2026)
III. Quarter		 (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter
Y / Y Investment Change TTM 32.89 % 31.34 % 27.68 % 21.9 % 15.17 %
Y / Y Net Income Change TTM 205.05 % 1583.88 % - - -
Investment (TTM) in Millions 791 725 669 624 589
Return On Investment (TTM) 15.6 % 12.38 % 12.05 % 10.45 % 6.8 %
KNSA's Overall Ranking # 269 # 582 # 417 # #
Seq. Investment Change TTM 7.77 % 7.49 % 7.38 % 6.84 % 6.52 %
Seq. Net Income Change TTM 35.84 % 10.4 % 23.82 % 64.28 % 649.85 %
Net Income (TTM) in Millions 110 81 73 59 36

KNSA Company Profile >> Back to KNSA Roi Comparisons >> See Annual KNSA Return On Investment



Return On Investment KNSA's Ranking
Within: No.
Industry # 10
Sector # 34
Overall # 269

Return On Investment Statistics
High Average Low
62.52 %
-11.61 %
-68.47 %
(Dec 31 2022)   (Dec 31 2021)







Financial Statements
Kiniksa Pharmaceuticals International Plc's III. Quarter Investments $ 791 Millions KNSA's Balance sheet
Kiniksa Pharmaceuticals International Plc's III. Quarter Income $ 47 Millions Quarterly KNSA's Income Statement
KNSA's Income by Division See KNSA's Income by Division


KNSA Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 624 480 463 413 185
Y / Y Investment Growth 30.11 % 3.73 % 12.13 % 122.66 % -40.75 %
Net Income in Millions 59 -43 14 183 -158
Y / Y Net Income Growth - - -92.32 % - -
Annual Return On Investment 9.45 % -9 % 3.04 % 44.44 % -85.22 %


Annual Roi Comment
In the fiscal year 2025 ROI improved to 9.45 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
KNSA's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for KNSA's Competitors
Subscribers only: Roi for Kiniksa Pharmaceuticals International Plc's Suppliers
Subscribers only: Return On Investment for KNSA's Customers

Other Ratios
KNSA's Roa KNSA's Inventory Turnover Ratio KNSA's Growth Rates KNSA's Dividend Statistics
KNSA's Profitability Ratios KNSA's Asset Turnover Ratio KNSA's Dividend Growth
KNSA's Roe KNSA's Valuation Ratios KNSA's Financial Strength Ratios KNSA's Dividend Payout Ratio



Companies with similar Return On Investment at Sep 30 2026, within Healthcare Sector ROI
Medpace Holdings Inc   41.14 %
Rallybio Corporation  36.04 %
Eli Lilly And Company  32.00 %
Caredx Inc   30.65 %
Zevra Therapeutics Inc   29.88 %
Acadia Pharmaceuticals Inc   26.89 %
Protalix Biotherapeutics inc   26.06 %
Standard Biotools Inc   23.91 %
Electromed Inc   23.41 %
Iradimed Corporation  22.98 %
Corcept Therapeutics Inc  22.08 %
Resmed Inc   21.10 %
Alector Inc   20.83 %
Chemed Corporation  20.46 %
Halozyme Therapeutics Inc   19.64 %
Pro dex Inc   19.11 %
Dexcom Inc   18.92 %
Illumina Inc   18.74 %
Denali Therapeutics Inc   17.88 %
West Pharmaceutical Services Inc   17.65 %
Healthcare Services Group Inc   17.18 %
Neurocrine Biosciences Inc   16.94 %
Krystal Biotech Inc   16.91 %
Vertex Pharmaceuticals Inc  16.63 %
Sanuwave Health Inc   16.50 %
Intuitive Surgical Inc   16.30 %
Hca Healthcare Inc   15.54 %
Kiniksa Pharmaceuticals International Plc  15.45 %
Amgen Inc   13.64 %
Carlisle Companies Incorporated  13.64 %

Date modified: 2026-10-28T09:26:31+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.